Peter and Takako Jones Lab for FSHD
Peter and Takako Jones Lab
FSHD preclinical testing
Development of FSHD-like models and preclinical testing of novel FSHD therapeutics.
FSHD pathogenic mechanisms
The molecular mechanisms driving FSHD pathology are being identified and are revealing new therapeutic avenues.
Epigenetic regulation
FSHD is a spectacular model for investigating epigenetic gene regulation in human development and disease.
Welcome to the Peter and Takako Jones Lab for FSHD.
Facioscapulohumeral muscular dystrophy (FSHD) is the most prevalent muscular dystrophy that affects males and females, children and adults and affects ~1 million individuals worldwide. Currently there is no cure or ameliorative treatment. Our goal is to help change this through a multi-pronged approach to relieve key bottlenecks in the therapeutic pathway by 1) creating much-needed tools for FSHD preclinical testing (e.g., FSHD-like mouse models and large animal models), 2) developing novel FSHD-specific therapeutics (e.g., CRISPR-inhibition gene therapy and small molecule drugs targeting DUX4 expression), 3) identifying circulating biomarkers to aid in clinical trials, and 4) to make FSHD diagnostics affordable and accessible to the worldwide FSHD community.
About Our Lab
Learn more about the research we do in Nevada on muscular dystrophy and how we are working to develop medical treatments.
Research
The most common muscular dystrophy today is facioscapulohumeral—and we're trying to treat it.
Community Outreach
The Jones Lab is committed to finding a cure to FSHD, so we communicate with the public about this disease.